Intesa Sanpaolo Wealth Management lowered its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 79.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,902 shares of the biopharmaceutical company’s stock after selling 97,300 shares during the period. Intesa Sanpaolo Wealth Management’s holdings in Pfizer were worth $710,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its position in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the last quarter. State Street Corp lifted its stake in Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Pfizer by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after acquiring an additional 3,999,646 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Pfizer in the 2nd quarter valued at $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pfizer by 4.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock valued at $870,668,000 after acquiring an additional 1,634,374 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Pfizer
Investors following PFE have been watching these headlines:
- Positive Sentiment: Pfizer secured exclusive rights outside Greater China to Starna Therapeutics’ three investigational in vivo CAR-T programs for autoimmune diseases. The agreement includes a $330 million upfront payment and up to $2.3 billion in potential milestones, adding a novel approach to Pfizer’s pipeline. Because the programs are preclinical, any commercial payoff is likely years away and uncertain. Article: Pfizer Secures Exclusive Rights To In Vivo CAR T Autoimmune Programs
- Positive Sentiment: A recent analysis said Pfizer’s launched and acquired products grew 32% in the third quarter, suggesting newer medicines are gaining traction and could help offset pressure on older products and COVID-related revenue. Article: Pfizer's Launched and Acquired Drugs Grew 32% in Q3
- Negative Sentiment: Technical indicators cited in a market update showed weak near-term momentum, with daily signals at “Strong Sell” and hourly signals at “Sell.” That may weigh on sentiment even as Pfizer pursues pipeline growth. Article: Pfizer near-term support and resistance levels
Pfizer Stock Performance
NYSE:PFE opened at $27.41 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42. The stock has a market capitalization of $156.25 billion, a PE ratio of 39.16, a P/E/G ratio of 1.90 and a beta of 0.31. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $31.44. The company has a fifty day moving average of $28.82 and a two-hundred day moving average of $27.03.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.13. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.87 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is currently 245.71%.
Wall Street Analyst Weigh In
PFE has been the topic of several recent research reports. Cantor Fitzgerald upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. DZ Bank lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, November 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, November 14th. Finally, FBN Securities set a $34.00 target price on Pfizer in a research note on Friday, November 6th. Six research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $30.32.
Check Out Our Latest Analysis on Pfizer
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
See Also
- Five stocks we like better than Pfizer
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
